Blood Clots (DVT & PE) in New Jersey: Diagnosis, Treatment & Prevention at Apex Heart & Vascular Care
By Dr. Anuj Shah, Apex Heart & Vascular CareA Hidden Threat That Demands Attention
Every year in the United States, an estimated 900,000 people develop a venous blood clot—either deep vein thrombosis (DVT) or pulmonary embolism (PE). Blood clots contribute to up to 100,000 deaths annually if untreated or mis‑managed. Globally, thrombotic conditions (including arterial events such as heart attacks and strokes) account for approximately one in every four deaths.
At Apex Heart & Vascular Care, we believe that awareness is only the first step: fast detection, guideline‑based treatment, and long‑term prevention are what truly save lives.
Understanding DVT & PE
Deep Vein Thrombosis (DVT) occurs when a blood clot forms in a deep vein—most commonly in the leg or pelvis. Signs can include one‑sided swelling, pain, warmth, redness, or heaviness in the limb.
Pulmonary Embolism (PE) arises when a clot dislodges and travels to the lungs, blocking blood flow. Symptoms may include sudden shortness of breath, chest pain (often worse on breathing), rapid heart rate, fainting, or even shock.
Risk factors for VTE (venous thromboembolism) are many: surgery or major trauma, hospitalization or prolonged immobility, cancer (especially with chemotherapy), hormone therapy (including birth control or hormone replacement), pregnancy and postpartum, inherited clotting disorders (thrombophilia), obesity, long‑haul travel, varicose veins or chronic venous insufficiency.
Because of the potential severity, rapid evaluation and treatment of suspected DVT or PE are essential.
Our Care Model: Fast, Coordinated, Evidence‑Based
At Apex Heart & Vascular Care (serving North New Jersey), we implement a streamlined approach for patients with suspected or confirmed venous thromboembolism (VTE):
- Rapid assessment and imaging
We offer same‑day access to Doppler ultrasound for suspected DVT and CT pulmonary angiography (CT‑PA) for suspected PE. Patients are triaged with risk stratification including right‑heart strain markers, troponin/BNP, and clinical scores (such as the simplified Pulmonary Embolism Severity Index [sPESI]). Early identification of high‑risk features (e.g., RV dysfunction) ensures timely intervention. - Multidisciplinary team (PERT‑style)
We deploy a PERT (Pulmonary Embolism Response Team)‑style approach: cardiology, vascular, hematology, interventional radiology/cardiology, and pulmonary specialists work together to tailor therapy. This team collaboration streamlines decision‑making and improves outcomes in intermediate‑high and high‑risk PE. - Evidence‑based therapy selection
- First‑line anticoagulation: For most DVT/PE cases, we start a Direct Oral Anticoagulant (DOAC) such as rivaroxaban, apixaban or edoxaban, based on patient renal/hepatic status, drug interactions, bleed risk, and insurance coverage. The shift to DOACs is supported by current major society guidelines.
- Extended prevention: In patients at increased risk of recurrence, extending anticoagulation beyond the initial 3‑6 months (“secondary prevention phase”) is often indicated.
- Advanced intervention: In certain circumstances—such as massive PE with hemodynamic compromise, intermediate‑high risk PE with right‑ventricular dysfunction, or limb‑threatening iliofemoral DVT—we consider catheter‑based or mechanical thrombus removal strategies. For DVT, the landmark ATTRACT trial showed that routine catheter‑directed thrombolysis (CDT) for proximal DVT did not reduce post‑thrombotic syndrome when used broadly—guiding us to more selective use of intervention.
- Filter use & post‑treatment care: For patients in whom anticoagulation is contraindicated (e.g., active bleeding, major trauma) or who experience recurrent clot despite adequate anticoagulation, we may place a retrievable inferior vena cava (IVC) filter — always with a retrieval plan. Post‑treatment, we monitor for complications such as chronic thromboembolic pulmonary hypertension (CTEPH), post‑thrombotic syndrome, and coordinate with hematology/vascular for long‑term care.
- Long‑term monitoring & prevention
After the acute phase, our focus turns to preventing recurrence and minimizing late complications:- Patient education on travel and immobility precautions, hydration, early mobilization after surgery/hospitalization, and weight management/smoking cessation.
- Coordination with primary care/hospital teams for risk reassessment, bleeding risk monitoring, and duration of anticoagulation decision‑making.
- Follow‑up imaging (when indicated), compression therapy for leg symptoms, and referral for venous ablation or sclerotherapy in patients with underlying chronic venous disease.
Real‑World Signs: When to Call Us or Go to the ER
Call 973‑916‑0002 (Apex) or present to your nearest emergency department immediately if you experience any of these:
- Sudden onset shortness of breath, chest pain, or fainting (possible PE)
- New swelling, pain, redness of one leg (possible DVT)
- Symptoms following recent surgery/hospitalization, long‑haul travel, or immobility
- Sudden rapid heart rate, low blood pressure, confusion
Early recognition and treatment are vital—delays increase mortality and complication risk. According to CDC data, sudden death is the first symptom in about 25% of people who have a PE.
Why These Treatments Work: Diving into the Evidence
DOACs (Direct Oral Anticoagulants)
- For example, the EINSTEIN‑DVT trial (3,449 patients) found recurrent VTE in 2.1% (rivaroxaban) vs 3.0% (standard therapy) with hazard ratio 0.68 (95% CI 0.44‑1.04; p < 0.001 for non‑inferiority).
- The pooled analysis of EINSTEIN‑DVT and EINSTEIN‑PE (8,282 patients) found 2.1% vs 2.3% recurrence (HR 0.89; 95% CI 0.66‑1.19) and major bleeding 1.0% vs 1.7% (HR 0.54; p = 0.002).
- These data underpin the modern shift away from warfarin toward DOACs for many patients, given simplified dosing, fewer interactions, and no routine INR monitoring.
- Guidelines (CHEST 2021 update) recommend DOACs (apixaban, dabigatran, edoxaban, rivaroxaban) over VKAs in most cases of acute VTE in patients without cancer.
Extended Anticoagulation & Recurrence Risk
Venous thromboembolism is not always a one‑time event. In one study of Olmsted County (MN, USA) residents, the cumulative incidence of first recurrence was 12.9% at 1 year, 16.6% at 2 years, 22.8% at 5 years, and 30.4% at 10 years. That data emphasizes the need to decide carefully on anticoagulation duration—balancing recurrence risk vs bleeding risk.
Interventional Therapies
- PEERLESS RCT: Compared large‑bore mechanical thrombectomy (LBMT) vs catheter‑directed thrombolysis (CDT) in intermediate‑high risk PE (≈ 550 patients) and found a win‑ratio of 5.01 (95% CI 3.68‑6.97) favouring LBMT, with fewer ICU admissions and similar bleeding rates.
- ATTRACT trial (DVT): Evaluated pharmacomechanical catheter‑directed thrombolysis in >1,000 patients with proximal DVT and found no significant reduction in post‑thrombotic syndrome (PTS), guiding us to restrict procedural intervention to carefully selected high‑risk DVT.
- Guidelines & Transitions of Care: The updated CHEST guideline (2021) provides 29 guidance statements covering the initial management, treatment phase, and extended phase of VTE. The American Society of Hematology (ASH) 2021 guideline also provides evidence‑based recommendations for VTE management in patients with cancer and without cancer. These guideline frameworks underpin our structured protocols at Apex—ensuring we provide modern, evidence‑based care.
A Deep Dive: Incidence, Risk, Complications & Costs
Incidence & Trends
- Annual incidence rates of VTE in Western countries are approximately 1‑2 per 1,000 persons per year (i.e., ~100‑200 per 100,000 person‑years) and rise with age.
- A modelling study estimated ~1,220,000 total VTE cases in the U.S. per year (~857,000 DVT; ~370,000 PE) based on 2016 data.
- The CDC reports up to 900,000 Americans affected annually and 60,000‑100,000 deaths.
- Hospitalization data from 2001‑2009 show VTE hospitalization rates rising steeply with age: about 1,134 per 100,000 in adults aged ≥80.
Risk & Recurrence
- VTE recurs in approximately 30% of patients within 10 years of the first event.
- Post‑thrombotic syndrome (PTS) occurs in ~25‑40% of patients after proximal DVT.
- Major morbidity and cost: One review estimated U.S. annual VTE‑related costs at $2 billion to $10 billion.
Why It Matters for Your Health
- VTE is the fifth most frequent cause for unplanned hospital readmissions after surgery and is a leading cause of preventable in‑hospital death.
- Considering the aging population, obesity epidemic, and increasing use of complex surgery and cancer therapies, the burden of VTE on patients and the healthcare system is projected to rise.
Apex Heart & Vascular’s Unique Strengths
- Comprehensive insurance acceptance: We accept all major carriers and work with patients across North New Jersey to ensure access.
- Availability six days a week: Our team has extended availability for same‑day imaging and intervention planning.
- Accreditations: We hold IAC‑certification multiple times and AAAASF certification, reflecting our procedural and facility excellence.
- Team depth: Our cardiologists, interventional vascular specialists, electrophysiologists, internal medicine providers, and vascular surgeons collaborate seamlessly—ideal for patients with overlapping cardiovascular and venous disease.
In short: At Apex, you get speed, coordination, and state‑of‑the‑art evidence‑based care.
Prevention & Long‑Term Care: What You Can Do
Risk Reduction Strategies
- Know your risks: If you’ve been hospitalized, immobilized, had major surgery, or have cancer, your VTE risk is elevated.
- Stay active & hydrate: Especially during long flights, car rides, or hospital stays—heel/foot pumps, walking every 1‑2 hours, drinking water.
- Ask your healthcare provider: “What am I doing to prevent blood clots?” This question matters after surgery, during chemotherapy, or if you have significant immobility.
- In fact, best practice prophylaxis (compression, anticoagulants when appropriate) can reduce VTE incidence by up to 70%.
- Support awareness: Share your story, encourage loved ones to watch for leg/cord symptoms, and ask about hospital/clinic protocols for VTE care.
Post‑Acute and Chronic Follow‑Up
- After initial anticoagulation (typically 3‑6 months), a decision must be made on duration: provoked vs unprovoked event, bleeding risk, patient preference.
- For patients with underlying chronic venous disease (varicose veins, venous insufficiency), consider referral for vein specialist—compression therapy, ablation, sclerotherapy—to reduce recurrence risk and improve leg symptoms.
- Monitor for complications: Post‑thrombotic syndrome (PTS), chronic thromboembolic pulmonary hypertension (CTEPH) after PE, and plan long‑term anticoagulation when indicated.
Frequently Asked Questions (FAQ)
Q. Is a swollen leg always a DVT?
Q. Which blood thinner is best for me?
Q. Do all clots need intervention (like thrombectomy or thrombolysis)?
Q. How long do I stay on treatment?
Q. What should I do to prevent a clot?
The Patient Story: Why It Matters
Imagine a 55‑year‑old woman who traveled on a 10‑hour flight, developed leg swelling the next day but ignored the discomfort, and then presented with shortness of breath two days later. CT‑PA showed a large PE with right‑heart strain. Thanks to rapid triage she receives DOAC therapy and is evaluated by our PERT team at Apex. We identify she has underlying venous insufficiency and a previously undiagnosed thrombophilia. We treat the acute event, then enroll her in a prevention program—compression therapy, referral for vein ablation, hematology follow‑up for thrombophilia—preventing recurrence and preserving quality of life. That could easily have been a fatal outcome—but timely recognition and coordinated care made the difference.
Final Thoughts
Blood clots are not random bad luck—they are predictable and often preventable. The key is knowledge + action. At Apex Heart & Vascular Care, we combine state‑of‑the‑art evidence (DOACs, mechanical therapies, multidisciplinary decision‑making) with real patient‑centered care and local accessibility in New Jersey.
If you’re experiencing leg swelling, chest symptoms, or have risk factors for thrombosis—or simply want a second opinion—call us at 973‑916‑0002. Early recognition saves lives; thoughtful care preserves quality of life.
References
- Centers for Disease Control and Prevention (CDC). Data & research: facts and statistics on blood clots.
https://www.cdc.gov/blood%E2%80%91clots/data%E2%80%91research/facts%E2%80%91stats/index.html - “Epidemiology and prevention of venous thromboembolism.” PMC.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579604/ - American College of Chest Physicians (CHEST) Antithrombotic Therapy for VTE Disease: 2021 update. Journal CHEST.
https://journal.chestnet.org/article/S0012‑3692(24)00292‑7/fulltext - “Epidemiology of venous thromboembolism.” PMC.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624298/ - “2021 Update to CHEST VTE Treatment Guidelines.” JWatch.
https://www.jwatch.org/na54097/2021/10/07/2021‑update‑chest‑vte‑treatment‑guidelines - ASH 2021 Guidelines for Management of VTE. Blood Advances.
https://ashpublications.org/bloodadvances/article/5/4/927/475194/ - “VTE epidemiology and challenges for VTE prevention.” ScienceDirect.
https://www.sciencedirect.com/science/article/pii/S2666572723000032 - “Incidence of venous thrombotic events and events of special interest.” BMJ Open.
https://bmjopen.bmj.com/content/12/2/e054669
Leave a Reply